Lenalidomide for aggressive B-cell lymphoma involving the central nervous system?

American Journal of Hematology

Volumn 86, Issue 11, 2011, Pages 957-957

  Cox, Maria Christina ^a   Mannino, Giuseppe ^a   Lionetto, Luana ^a   Naso, Virginia ^a   Simmaco, Maurizio ^a   Spiriti, Maria Antonietta Aloe ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD5 ANTIGEN; CYTARABINE; DEXAMETHASONE; FLUORINE; IFOSFAMIDE; LENALIDOMIDE; METHOTREXATE; RITUXIMAB;

AGED; ANGIOGRAPHY; ARTICLE; BLURRED VISION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CASE REPORT; CEREBROSPINAL FLUID CYTOLOGY; COMPUTER ASSISTED TOMOGRAPHY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG MEGADOSE; DRUG TREATMENT FAILURE; EXOPHTHALMOS; EYE BIOPSY; EYE EXAMINATION; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; LACRIMAL GLAND; LIQUID CHROMATOGRAPHY; MALE; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; ORBIT CANCER; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VISUAL ACUITY;

AGED; ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHROMATOGRAPHY, LIQUID; HUMANS; LYMPHOMA, MANTLE-CELL; MAGNETIC RESONANCE IMAGING; MALE; ORBIT; TANDEM MASS SPECTROMETRY; THALIDOMIDE;

EID: 80054023067     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22148     Document Type: Article

References (12)

1. Ferreri AJ, Assanelli A, Crocchiolo R, et al. Central nervous system dissemination in immunocompetent patients with aggressive lymphomas: Incidence, risk factors and therapeutic options. Hematol Oncol 2009; 27: 61-70.
2. Musuraca G, Fattori PP, Ceccolini M. Prolonged 18FDG-PET negative complete remission in a heavily pretreated, elderly patient with diffuse large B cell lymphoma treated with lenalidomide, low dose dexamethasone, and colony stimulating factor (Rd-G). Am J Hematol 2011; 86: 79-80.
3. Habermann TM, Lossos IS, Justice G. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 2009; 145: 344-349.
4. Zeldis JB, Knight R, Hussein M, et al. A review of the history, properties, and use of the immunomodulatory compound lenalidomide. Ann N Y Acad Sci 2011; 1222: 76-82.
5. Zhang L, Qian Z, Cai Z, et al. Synergistic antitumor effects of Lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo†. A m J Hematol 2009; 84: 553-559.
6. Rubenstein JL, Treseler PA, Stewart PJ. Regression of refractory intraocular large B-cell lymphoma with lenalidomide monotherapy. J Clin Oncol 2011; 29: e595-e597.
7. Ott G, Kalla J, Ott MM, Schryen B, Katzenberger T, Müller JG, Müller-Hermelink HK. Blastoid variants of mantle cell lymphoma: Frequent bcl-1 rearrangements at the major translocation cluster region and tetraploid chromosome clones. Blood 1997; 89: 1421-1429.
8. Zhang MM, Gopal AK. Radioimmunotherapy-based conditioning regimens for stem cell transplantation. Semin Hematol 2008; 45: 118-1125.
9. Hon C, Au WY, Ma ES, Unusual sites of involvement in non-Hodgkin's lymphoma, Case 1. Isolated orbit relapse after allogeneic bone marrow transplantation for malignant lymphoma. J Clin Oncol 2002; 20: 4394-4395.
10. Jahnke K, Thiel E, Abrey LE, et al. Diagnosis and management of primary intraocular lymphoma: An update. Clin Ophthalmol 2007; 1: 247-258.
11. Precupanu CM, Validire P, Lévy C, Primary high-grade ocular adnexal lymphoma: Clinicopathological characteristics and prognostic factors of a single-centre series. Am J Hematol 2010; 85: 372-375.
12. Ferreri AJ. How I treat CNS lymphoma. Blood 2011; 118: 510-522.